Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units convertible to common stock, as reported in a recent SEC Form 4 filing.

Summary

• Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., reported a transaction on March 22, 2024.
• The transaction involved the acquisition of 175.0468 deferred stock units.
• These units represent the right to receive one share of Elanco common stock or the cash equivalent upon termination of employment or during a specified future year.
• The price of the deferred stock units was $15.82.
• Following the transaction, Simmons directly owns 1,046.4709 deferred stock units.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings of company executives and directors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive compensation and ownership.

Key Dates